Pirfenidone Tablet, Coated
Product Images NDC 62332-480

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 62332-480). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

500 Tablets (Pirfenidone 267 mg)

Pirfenidone Tablets 267 mg coated tablets label by Alembic Pharmaceuticals Inc. The label indicates a bottle containing 500 tablets with dosage strength 267 mg. It includes storage instructions, manufacturer details, and barcode information on the right side.*

FDA Label Image

500 Tablets (Pirfenidone 801 mg)

Label for Pirfenidone Tablets 801 mg oral coated tablets by Alembic Pharmaceuticals Inc. The label states the product contains 801 mg of pirfenidone per film-coated tablet and comes in a package of 500 tablets. It includes storage instructions, dosage reference to the package insert, lot and expiration information, and manufacturer details from Alembic Pharmaceuticals Limited in India and Alembic Pharmaceuticals, Inc. in the USA.*

FDA Label Image

Figure 1 (Pirfenidone Figure1)

A cumulative distribution curve showing the percent of patients versus absolute change in percent predicted forced vital capacity (%FVC) from baseline to week 52. Two groups are compared: Pirfenidone (n=278) represented by a solid line and placebo (n=277) by a dotted line. The x-axis ranges from -30% to +10% change in %FVC, with worsening indicated by decreases and no decline by increases. Specific percentile points are marked, such as 32% and 17% worsening at around -10%, and 90% and 77% with no decline near 0% change.*

FDA Label Image

Figure 2 (Pirfenidone Figure2)

A line graph comparing the mean change in Forced Vital Capacity (FVC) in mL over 52 weeks between two groups: Pirfenidone (n=278) and Placebo (n=277). The graph shows a decreasing trend for both groups, with the placebo group experiencing a greater decline in FVC over time compared to the Pirfenidone group.*

FDA Label Image

Figure 3 (Pirfenidone Figure3)

A Kaplan-Meier survival curve plot showing the percentage of patients alive over time in weeks. It compares Pirfenidone (solid line) with placebo (dotted line), including the number of patients at risk at various time points and a hazard ratio (HR) with 95% confidence interval (CI) indicated on the graph.*

FDA Label Image

Pirfenidone (Pirfenidone Structure)

Chemical structure of Pirfenidone, showing its molecular arrangement including benzene rings and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.